HOSPITAL
FORMULARY
FOR HOSPITAL AND MANAGED CARE DECISION MAKERS

SUBJECT INDEX TO VOLUME 28

A

acromegaly, octreotide for Tx of, 326 (Apr)
adenosine, ectopic atrial tachycardia, for Tx of, 441 (May)
adverse drug reactions
  costs of monitoring, in patients with rheumatoid arthritis, 13 (Jan)
  new reporting system for, 668 (Aug)
  study of, in hospitalized patients (abstr), 943 (Nov)
Agency for Health Care Policy and Research, guidelines and outcomes research developed by, 933 (Nov)
AIDS
  clarithromycin for Tx of MAC bacteremia in patients with, 237 (Mar)
  costs of treating patients with, 821 (Oct)
  granulocyte-macrophage colony-stimulating factor prevents Tx-induced neutropenia in patients with (abstr), 97 (Jan)
  HGP-30 vaccine for immunotherapy against, 828 (Oct)
  new drugs for Tx of, Community-Based Clinical Trial Network accelerates, 216 (Mar)
  research for Tx of, 325 (Apr); 611 (Jul)
  treatment of, 242 (Mar)
  trimethoprim/sulfamethoxazole sensitivity, less likely in patients severely ill with (abstr), 512 (May)
albuterol sulfate, Volmax, update on, 816 (Oct)
alcohol dependence, naltrexone HCl for Tx of, 114 (Feb)
alclometasone dipropionate 0.05% cream and 0.05% ointment, Aclovate, update on, 410 (May)
Alzheimer's disease, tacrine for Tx of, nearing approval, 544 (Jun)
amikacin, once daily regimen, with ceftriaxone, in Tx of granulocytopenia, 956 (Dec)
aminoglycoside dosing services, benefits of, questioned (abstr), 653 (Jul)
amiodarone, angina, as adjunct in Tx of (abstr), 709 (Aug)
amlodipine besylate, Norvasc, update on, 8 (Jan)
angina
  amiodarone as adjunct in Tx of (abstr), 709 (Aug)
  combination medical therapy in the Tx of, 34 (Jan)
  nicorandil as alternative for the Tx of, 16 (Jan)
angioplasty, plus IV thrombolytic therapy, vs angioplasty alone, 217 (Mar)
antiarrhythmics, risk vs benefit of, in Tx of atrial fibrillation in CHF (abstr), 97 (Jan)
antibiotics
  benefits of extending dosing intervals of, 648 (Jul)
  conducting reviews of, 222 (Mar); 228 (Mar)
  elderly, use of, in, 754 (Sept)
  post-appendectomy, home administration of, in children, 824 (Oct)
  sales of, 13 (Jan)
  streamlining program for, 868 (Oct)
  surveillance program for, 821 (Oct)
  use of computers in selection of, 237 (Mar)
anticoagulant therapy, duration of, for post-op deep vein thrombosis or pulmonary embolism (abstr), 96 (Jan)
antiemetic agents, serotonin receptor agonists, use of, as, 988 (Dec)
antiepileptic drugs, seizure disorders, use of, in the management of, 154 (Feb)
antihemophilic factor, recombinant
  Kogenate, update on, 410 (May)
  Recombinate, update on, 113 (Feb)
antihyperlipidemic agents, costs, safety, and efficacy of, 262 (Mar)
antihypertensives, bisoprolol, focus on, 453 (May)
antineoplastic agents, off-label uses for, 641 (Jul)
arthritis, rheumatoid, costs of monitoring therapy of patients with, 13 (Jan)
aspirin
  low-dose, for patency after coronary artery bypass grafts, 16 (Jan)
  needed doses of, vary for stroke prevention (abstr), 709 (Aug)
astemizole, Hismanal, update on, 8 (Jan)
asthma
  controversy regarding Tx of (letter), 395 (Apr)
  salmeterol for Tx of (abstr), 296 (Mar); 741 (Sept)
atenolol, silent ischemia, reduces cardiac events in patients with, 437 (May)
atovaquone
  focus on, 341 (Apr)
  Mepron, update on, 109 (Feb)
atrial fibrillation in CHF, risk vs benefit of antiarrhythmics in Tx of (abstr), 97 (Jan)
azithromycin
  doxycycline, vs, for Tx of chlamydia (abstr), 97 (Jan)
  terfenadine, and its apparent lack of interaction with, 617 (Jul)

B

bacteremia, combination therapy with antibiotic active against *Klebsiella* needed for patients with severe (abstr), 511 (May)
balanced salt solution with bicarbonate dextrose and glutathione, AMO Endosol Extra, update on, 109 (Feb)
beta blockers, ophthalmic, cardiovascular risk and use of, 617 (Jul)
biologics, importance of information regarding newly approved (letter), 507 (May)
biotechnology products
  government proposal may limit research funds for development of, 956 (Dec)
  managing use of, 773 (Sept)
  planning for launch of, 218 (Mar)
bisoprolol, focus on, 453 (May)
bone marrow transplantation, colony-stimulating factors reduce risk of, 312 (Apr)
Breakthrough Drug Committee, health care reform, and, 946 (Nov)
buprenorphine HCl, Buprenex, update on, 810 (Oct)

C

cancer
  breast
    clodronate for Tx of skeletal morbidity in (abstr), 510 (May)
    elderly women, in, adjuvant chemotherapy for, 797 (Sept)
    tamoxifen for Tx of elderly patients with (abstr), 510 (May)
  colorectal, prevention and Tx of, 354 (Apr)
  ovarian, combination chemotherapy for Tx of (abstr), 400 (Apr)
candidiasis, vaginal, itraconazole for Tx of (abstr), 400 (Apr)
captopril, Capoten, update on, 880 (Nov)
cardiac arrest, high-dose epinephrine, use of, after (abstr), 293 (Mar)
cardiovascular drugs, number of, expected to rise, 217 (Mar)
carisoprodol, risk of abuse with (abstr), 944 (Nov)
cefazolin, prophylaxis, as, in cesarean section, 285 (Mar)
cefixime
  bacterial sinus infections, for Tx of (abstr), 798 (Sept)
  Suprax, update on, 412 (May)
cefmetazole sodium, Zefazone, update on, 606 (Jul)
cefotetan disodium, Cefotan, update on, 811 (Oct)
cefpodoxime proxetil, Vantin, update on, 816 (Oct)
cefprozil, Cefzil, update on, 666 (Aug)
ceftizoxime sodium
  Cefizox, update on, 7 (Jan)
  cefoxitin, as alternative to (abstr), 792 (Sept)
ceftriaxone sodium
  amikacin, with, as once daily regimen for Tx of granulocytopenia, 956 (Dec)
  IV, DUE of, 180 (Feb)
  Rocephin, update on, 883 (Nov)
cefuroxime, doxycycline, vs, for Tx of Lyme disease (abstr), 98 (Jan)
cesarean section, antibiotic prophylaxis in, 285 (Mar)
chlamydia, azithromycin vs doxycycline for Tx of (abstr), 97 (Jan)
ciprofloxacin, TMP-SMZ, vs, for Tx of UTIs (abstr), 511 (May)
ciprostene, percutaneous transluminal coronary angioplasty, beneficial for use after, 441 (May)
cisapride, Propulsid Tablets, update on, 816 (Oct)
cladribine
  focus on, 621 (Jul)
  Leustatin, update on, 411 (May)
clarithromycin
  DUE of, as sequential therapy, 999 (Dec)
  MAC bacteremia in AIDS patients, for Tx of, 237 (Mar)
clindamycin/amikacin, sulbactam/ampicillin, vs, in head-neck surgery (abstr), 98 (Jan)
clindamycin phosphate USP, 1%, Clinda-Derm, update on, 605 (Jul)
clinical pharmacology consult service (CPCS), formulary management, use of, in, 699 (Aug)
clinical trials, influence of methods used in presenting results of, 122 (Feb)
clodronate, oral, for Tx of skeletal morbidity in breast cancer patients (abstr), 510 (May)
colestipol, simvastatin, or, vs combination of both for hypercholesterolemia, 21 (Jan)
colloid, volume expansion, for, 503 (May)
colony-stimulating factors, bone marrow transplantation, reduce risk of, 312 (Apr)
complete high-protein liquid nutrition, with and without fiber, Replete and Replete with fiber, update on, 606 (Jul)
computers, use of, in antibiotic selection, 237 (Mar)
congestive heart failure
  chronic, flosequinan efficacious in, 15 (Jan)
  digoxin, withdrawal of, in patients with (abstr), 944 (Nov)
  milrinone for Tx of, 896 (Nov)
  nicardipine shows promise for Tx of, 442 (May)
contrast agents, nonintrathecal, FDA requests boxed warnings for, 605 (Jul)
controlled substances, controversy regarding increased fees for dispensing, 826 (Oct)
convergent combination therapy, HIV infection, for Tx of, 418 (May)
coronary artery bypass grafts
  low-dose aspirin for maintaining patency after, 16 (Jan)

superior to drug treatment alone for improving physical activity, 437 (May)
Crohn's disease, oral mesalamine prevents relapse in (abstr), 709 (Aug)
cytomegalovirus immune globulin (human), CytoGam, update on, 207 (Mar)
cytomegalovirus infection, ganciclovir/foscarnet combination for Tx of, in AIDS patients (abstr), 797 (Sept)
cytomegalovirus retinopathy, AIDS-related, ganciclovir slows progression of (abstr), 190 (Feb)

D

dapsone-pyrimethamine, pentamidine, compared with, for prevention of PCP and toxoplasmosis in AIDS patients (abstr), 792 (Sept)
data collection, electronic, increase of, 970 (Dec)
daunorubicin, liposomal, DaunoXome, update on, 666 (Aug)
deep vein thrombosis
anticoagulant therapy, duration of, in (abstr), 96 (Jan)
enoxaparin as alternative Tx for, 545 (Jun)
depression, improving patient compliance and outcome in Tx of, 968 (Dec)
desogestrel and ethinyl estradiol, Desogen, update on, 109 (Feb)
diarrhea, *C difficile*-associated
antibiotic-linked (abstr), 295 (Mar)
teicoplanin vs vancomycin for Tx of (abstr), 189 (Feb)
diclofenac/misoprostol, gastroduodenal ulcers, reduces, in osteoarthritic patients (abstr), 294 (Mar)
didanosine (ddI)
timing of administration of, in HIV infection (abstr), 96 (Jan)
Videx, update on, 13 (Jan)
diflorasone diacetate, Psorcon Cream 0.05%, update on, 411 (May)
digoxin, withdrawal of, in patients with CHF (abstr), 944 (Nov)
dihydroergotamine mesylate, migraine, for Tx of, 887 (Nov)
dinoprostone cervical gel, Prepidil Gel, update on, 210 (Mar)
diphtheria, tetanus, pertussis and *H influenzae* vaccine, Tetramune, update on, 606 (Jul)
doxorubicin HCl, filtration system for administration of, 120 (Feb)
doxycycline
azithromycin, vs, for Tx of chlamydia (abstr), 97 (Jan)
cefuroxime, vs, for Tx of Lyme disease (abstr), 98 (Jan)
Vibramycin, update on, 666 (Aug)
dronabinol, Marinol, update on, 210 (Mar)
drug costs
analyses of, decision makers need to understand, 131 (Feb)
competition reduces increases in, 668 (Aug)
health care reform and, 427 (May); 1014 (Dec)
health maintenance organizations, in, 326 (Apr)
moderating, 321 (Apr)
plans for reducing, in Ontario, Canada, 886 (Nov)
drug monitoring, state Medicaid programs and, 120 (Feb)
drug reference, revised, available, 217 (Mar)
drug usage evaluation (DUE)
ceftriaxone IV, of, 180 (Feb)
clarithromycin as sequential therapy, of, 999 (Dec)
colloid for volume expansion, of, 503 (May)
fluconazole, of, 499 (May)
H_2 antagonists, of, 86 (Jan)
reducing costs of, 789 (Sept)
Drug Use Review Program (Medicaid)
effectiveness of, in curtailing improper drug use, 538 (Jun)
pharmacist associations urge changes to, 312 (Apr); 428 (May)
drug utilization management program, components for a successful, 136 (Feb)
drugs
high-cost, and formulary considerations, 221 (Mar)
high-cost, rational use of, 228 (Mar)
high-tech, high-cost, legal perspectives on, 221 (Mar)
new, determining "value" of, 731 (Sept)

E

elderly
antibiotics, use of, in, 754 (Sept)
nabumetone, safety of, in treating, 888 (Nov)
new drugs for the Tx of, 670 (Aug)
enalapril, ischemic events, reduces, in patients with low ejection fractions (abstr), 401 (Apr)
enalaprilat, IV, role of, in lowering blood pressure, 173 (Feb)
enoxacin, use of, in patients undergoing chemotherapy, 653 (Jul)
enoxaparin
focus on, 545 (Jun)
Lovenox, update on, 526 (Jun)
eosinophilic folliculitis, itraconazole for Tx of, 833 (Oct)
epilepsy, felbamate for Tx of, 837 (Oct)
epinephrine, after cardiac arrest, use of high-dose (abstr), 293 (Mar)
epoetin alfa, Procrit, update on, 526 (Jun)
erythromycin 2% topical gel, Emgel, update on, 410 (May)
estropipate, Ogen, update on, 113 (Feb)
etodolac, Lodine, update on, 883 (Nov)

F

Factor VIII and IX replacement products, Vetter Lyo-Ject, update on, 114 (Feb)
Factor VIII, high-purity, HIV-infected hemophiliacs, for Tx of, 325 (Apr)
felbamate
Felbatol, update on, 811 (Oct)
focus on, 837 (Oct)
fetal tissue
federal funding for research with, 216 (Mar)
Parkinson's disease, use of, for Tx of (abstr), 294 (Mar); 612 (Jul)
flosequinan
chronic heart failure, efficacious in the Tx of, 15 (Jan)
Manoplax, update on, 208 (Mar); 526 (Jun); 666 (Aug)
NSAID therapy, may relieve adverse renal effects of, 451 (May)
fluconazole, dosing of, in renal impairment, 499 (May)
flumazenil, Mazicon/Romazicon IV, update on, 883 (Nov)
fluoroquinolones, safety of (letter), 291 (Mar)
fluoxetine, Prozac, update on, 215 (Mar)
fluticasone propionate 0.005% ointment and 0.05% cream, Cutivate, update on, 410 (May)
formularies
California state, 325 (Apr)
compliance with, guidelines for encouraging, 433 (May)
cost containment efforts under health care reform, role in, 1014 (Dec)
development process, evolution of, 435 (May)
high-cost additions, conducting a review for, 221 (Mar)
management of, 218 (Mar); 219 (Mar); 227 (Mar); 228 (Mar); 429 (May); 434 (May); 699 (Aug)
Medicaid, and restrictive, 713 (Aug); 800 (Sept)
national, controversy regarding policy for, 610 (Jul)
national versus local, 671 (Aug)
role of, expected to change, 135 (Feb)
structured decision-making processes for developing, 859 (Oct)
foscarnet sodium, ganciclovir, vs, for Tx of cytomegalovirus GI infection, 833 (Oct)

G

gadodiamide, Omniscan, update on, 210 (Mar)
gadopentetate dimeglumine, Magnevist, update on, 883 (Nov)
gadoteridol injection, ProHance, update on, 113 (Feb)
ganciclovir/foscarnet, combination of, for Tx of cytomegalovirus infections in AIDS patients (abstr), 797 (Sept)
ganciclovir sodium
AIDS-related cytomegalovirus retinopathy, slows progression of (abstr), 190 (Feb)
foscarnet, vs, for Tx of cytomegalovirus GI infection, 833 (Oct)
gastroesophageal reflux disease, omeprazole in the Tx of, 725 (Sept)
generic drugs
debate on, continues, 328 (Apr)
FDA bioequivalence standards for, 417 (May)
global budgeting
granulocyte colony-stimulating factor, Kaposi's sarcoma, in Tx of, 827 (Oct)
granulocyte-macrophage colony-stimulating factor
AIDS, prevents Tx-induced neutropenia in patients with (abstr), 97 (Jan)
leukopenia, reduces severe (abstr), 402 (Apr)
granulocytopenia, once daily antibiotic regimen shows efficacy in Tx of, 956 (Dec)
GUSTO (Global Utilization of Streptokinase and t-PA for Occluded Arteries trial)
discussion regarding, 558 (Jun)
findings of, 543 (Jun)
findings of, questioned, 543 (Jun)

H

H_2 antagonists, DUE of, 86 (Jan)
Haemophilus b conjugate vaccine (tetanus toxoid conjugate), ActHIB, update on, 600 (Jul)
health care reform
Breakthrough Drug Committee and, 946 (Nov)
Clinton's plan for, 311 (Apr)
drug costs and, 427 (May)
drug usage policies and benefit coverage in, compared, 728 (Sept)
formularies and rebates lead drug cost containment efforts under, 1014 (Dec)
insurance industry, and, 330 (Apr)
pharmaceutical industry, and, 872 (Oct)
pharmaceutical organizations urge pharmaceutical coverage in, 544 (Jun)
pharmacists' role under, 737 (Sept)
pharmacy associations' coalitions voice concerns

regarding, 608 (Jul)
proposal supported by pharmacist and group health organizations, 956 (Dec)
health maintenance organizations (HMOs), drug costs in, 326 (Apr)
hemophilia A, high-purity Factor VIII for Tx of, in HIV-infected patients, 325 (Apr)
heparin
low molecular weight, use of, after knee arthroplasty, 608 (Jul)
pharmacy-managed use of, 417 (May)
hepatitis B, chronic, viral interferon alfa-2b for Tx of (abstr), 402 (Apr)
hepatitis B vaccine, Recombivax HB, update on, 816 (Oct)
high-caloric density hepatic diet, NutriHep, update on, 606 (Jul)
hirudin, thrombolysis, as adjunct to, 451 (May)
histoplasmosis, AIDS-related, itraconazole for Tx of, 241 (Mar)
histrelin acetate, Supprelin, update on, 215 (Mar)
HIV infection
convergent combination therapy for Tx of, 418 (May)
costs of treating, 13 (Jan)
didanosine, timing of administration of, in (abstr), 96 (Jan)
isoniazid prophylaxis for Tx of tuberculin reactors with (abstr), 510 (May)
treatment of, 242 (Mar)
trimethoprim/sulfamethoxazole desensitization and, 14 (Jan)
zidovudine, early use of, in patients with, 828 (Oct)
hospital pharmacies, rising purchases, inventories of, 311 (Apr)
hospitals, efficiency of, 428 (May)
hydromorphone HCl, Dilaudid, update on, 811 (Oct)
hypercholesterolemia
colestipol vs simvastatin vs combination of both for Tx of, 21 (Jan)
simvastatin for Tx of (abstr), 296 (Mar)
hyperlipidemia, diagnosis and Tx of, 262 (Mar)
hypertension
enalaprilat, role of, in the Tx of, 173 (Feb)
recommendations for therapy of, 120 (Feb); 888 (Nov)
stepped care approach to Tx of, challenged, 672 (Aug)

I

indapamide, Lozol, update on, 722 (Sept)
infections
bone and joint, therapy of, 63 (Jan)
candidal, prevention and treatment of, 914 (Nov)
fungal, itraconazole for Tx of, 23 (Jan)
gram-negative, severe systemic inflammatory response syndrome, may not be present in patients with (abstr), 512 (May)
Helicobacter pylori
combination therapy for Tx of (abstr), 295 (Mar)
ulcer disease and, Tx options for, 632 (Jul); (letter), 780 (Sept)
HIV: See HIV infection
nosocomial, prevention of, 114 (Feb)
urinary tract, ciprofloxacin vs TMP/SMZ for Tx of (abstr), 511 (May)
inflammatory bowel disease, therapies for, 466 (May)
inotropic medications, low cardiac output states, for management of, 388 (Apr)
interferon alfa-2b, chronic viral hepatitis B, for Tx of (abstr), 402 (Apr)
interferon beta-1b
Betaseron, update on, 810 (Oct)
multiple sclerosis, for Tx of (abstr), 943 (Nov)
interleukin-1 receptor antagonist (IL-1ra), sepsis, increases survival rate in, 241 (Mar)
ischemia, silent, atenolol reduces cardiac events in patients with, 437 (May)
isoniazid, prophylaxis with, for use in HIV-infected tuberculin reactors (abstr), 510 (May)
isosorbide dinitrate, infarct size, reduces, after myocardial infarction (abstr), 399 (Apr)
isosorbide mononitrate, Imdur, update on, 880 (Nov)
itraconazole
AIDS-related histoplasmosis, for Tx of, 241 (Mar)
eosinophilic folliculitis, for Tx of, 853 (Oct)
focus on, 23 (Jan)
Sporanox, update on, 412 (May)
vaginal candidiasis, for Tx of (abstr), 400 (Apr)

J

Japanese encephalitis virus vaccine inactivated, JE-VAX, update on, 208 (Mar)

K

Kaposi's sarcoma, recombinant granulocyte colony-stimulating factor for Tx of, 827 (Oct)
ketoconazole 2% cream, Nizoral, update on, 411 (May)
ketoprofen, Oruvail, update on, 962 (Dec)
ketorolac, IV, patient-controlled morphine, reduces need for, 612 (Jul)
ketorolac tromethamine 0.5% sterile ophthalmic solution, Acular, update on, 109 (Feb)

L

labor, mifepristone as alternative for inducing (abstr), 401 (Apr)
leukemia, hairy-cell, cladribine in the Tx of, 621 (Jul)
leukopenia, severe, granulocyte-macrophage colony-stimulating factor reduces (abstr), 402 (Apr)
leuprolide acetate, Lupron Depot-Ped, update on, 605 (Jul); (correction) 962 (Dec)
levocarnitine, Carnitor, update on, 307 (Apr)
levomethadyl acetate HCl oral solution, ORLAAM, update on, 815 (Oct)
lidocaine 2.5%/prilocaine 2.5% cream, EMLA Cream, update on, 207 (Mar)
lisinopril
nifedipine, vs, for Tx of hypertension, 824 (Oct)
Prinivil, Zestril, update on, 722 (Sept)
lomefloxacin, Maxaquin, update on, 815 (Oct)
loratadine
Claritin, update on, 600 (Jul)
focus on, 137 (Feb)
lorcarbacef, Lorabid, update on, 605 (Jul)
low cardiac output states, inotropic medications for management of, 388 (Apr)
low ejection fractions, enalapril reduces ischemic events in patients with (abstr), 401 (Apr)
Lyme disease, cefuroxime vs doxycycline for Tx of (abstr), 98 (Jan)
lymphoma, non-Hodgkin's, old vs new treatment regimens for, compared, 610 (Jul)

M

magnesium, routine administration of, not needed in all patients after myocardial infarction, 190 (Feb)
malpractice suits, pharmacy errors infrequently lead to, 725 (Sept)
managed care
information processing under, 967 (Dec)
pharmacoeconomics in, 671 (Aug)
reforms in, and Medicaid, 330 (Apr)
role of P & T Committees in, 963 (Dec)
role of pharmacists in, 537 (Jun), 967 (Dec)
managed competition, bill proposed, 329 (Apr)
masoprocol cream 10%, Actinex, update on, 7 (Jan)
Medicaid
drug monitoring systems and, 120 (Feb); 538 (Jun)
managed care reforms and, 330 (Apr)
Medi-Cal, changes in formulary of, 608 (Jul)
medroxyprogesterone acetate solution, Depo-Provera, update on, 8 (Jan)
megestrol acetate oral suspension, Megace, update on, 959 (Dec)
mephalen HCl
Alkeran, update on, 410 (May)
Alkeran IV, update on, 600 (Jul)
meprobamate/benzactyzine, Deprol, update on, 959 (Dec)
mesalamine
oral, for prevention of Crohn's disease relapse (abstr), 709 (Aug)
Pentasa, update on, 606 (Jul)
methicillin-resistant *S aureus*, nasal mupirocin for controlling outbreaks of, 242 (Mar)
midazolam, propofol, vs, in ICU sedation, 418 (May)
mifepristone (RU-486)
ban on, lifted, 216 (Mar)
labor, for inducing (abstr), 401 (Apr)
migraine
dihydroergotamine mesylate for Tx of, 887 (Nov)
sumatriptan for acute Tx of, 247 (Mar)
milrinone lactate injection
focus on, 896 (Nov)
Primacor IV, update on, 8 (Jan)
misoprostol, NSAID-induced ulcers, as prophylaxis against (abstr), 708 (Aug)
monoamine oxidase inhibitors, opioids, and interaction with, 692 (Aug)
monobenzone topical cream 20%, Benoquin, update on, 810 (Oct)
multiple sclerosis, interferon beta-1b for Tx of (abstr), 943 (Nov)
mupirocin, nasal, methicillin-resistant *S aureus*, for controlling outbreaks of, 242 (Mar)
murine monoclonal antibody E5, sepsis, for Tx of, 312 (Apr)
muromonab-CD3, Orthoclone, update on, 816 (Oct)
Mycobacterium avium complex, rifabutin for the Tx of, 827 (Oct); 975 (Dec)
myocardial infarction
isosorbide dinitrate reduces infarct size after (abstr), 399 (Apr)
ramipril for Tx of patients after, 889 (Nov)
routine magnesium not needed in all patients after, 190 (Feb)
routine streptokinase not needed after PTCA for acute (abstr), 509 (May)
thrombolytic, prehospital administration of, following, 21 (Jan)
tissue plasminogen activator, late administration of, reduces mortality from, 15 (Jan)
warfarin, use of, after acute, 890 (Nov)

N

nabumetone, safety of, in treating elderly patients, 888 (Nov)
nafarelin acetate nasal solution, Synarel, update on, 215 (Mar)
naltrexone HCl, alcohol dependence, for the Tx of, 114 (Feb)
nausea, chemotherapy-associated, ondansetron/dexamethasone combination for Tx of, 321 (Apr)
nedocromil sodium, Tilade Inhaler, update on, 215 (Mar)
new drug approvals
  1992, 125 (Feb)
  accelerated, for controlled-release drugs, 887 (Nov)
  Community-Based Clinical Trial Network accelerates, 216 (Mar)
  rising drug costs, and accelerated, 128 (Feb)
  user-fee bill and, 14 (Jan); 656 (Jul)
nicardipine, congestive heart failure, shows promise for Tx of, 442 (May)
nicorandil, angina, as alternative for Tx of, 16 (Jan)
nifedipine, lisinopril, vs, for Tx of hypertension, 824 (Oct)
nifedipine, extended-release, Adalat, update on, 810 (Oct)
nizatidine
  Axid Pulvules, update on, 7 (Jan)
  Medi-Cal removes from formulary, 325 (Apr)
nonsteroidal anti-inflammatory drugs, adverse renal effects of, flosequinan may relieve, 451 (May)
norgestimate/ethinyl estradiol, Ortho-Cyclen, update on, 113 (Feb)
nursing homes, decline in formularies used in, 611 (Jul)

O

octreotide acetate, acromegaly, for Tx of, 326 (Apr)
off-label drug uses, FDA reviews, 668 (Aug)
omeprazole
  gastroesophageal reflux disease, in Tx of, 725 (Sept)
  ranitidine, vs, for Tx of ulcers (abstr), 654 (Jul)
ondansetron HCl
  plus dexamethasone for Tx of chemotherapy-associated nausea, 321 (Apr)
  Zofran, update on, 311 (Apr); 412 (May); 883 (Nov)
opioids, monoamine oxidase inhibitors, and interaction with, 692 (Aug)
oxaprozin, Daypro, update on, 109 (Feb)
oxiconazole nitrate 1% lotion, Oxistat, update on, 210 (Mar); 411 (May)

P

P & T Committees, future of in managed care, 963 (Dec)
paclitaxel, Taxol, update on, 215 (Mar)
pain medications, influence of insurance coverage on physicians' prescribing of, 611 (Jul)
Parkinson's disease, fetal tissue, use of, in Tx of (abstr), 294 (Mar); 612 (Jul)
paroxetine HCl, Paxil, update on, 307 (Apr); 526 (Jun)
patient assistance programs
  directory of, available, 958 (Dec)
  how to find and use, 730 (Sept)
patient counseling, federal requirements for, 730 (Sept)
patient outcomes
  economic considerations and, in Tx of lower respiratory infections, 216 (Mar)
  improving, in Tx of depression, 968 (Dec)
  influence of
    on formulary decisions, 859 (Oct)
    on health care decisions, 533 (Jun)
  involvement of patients and MDs in improving, 538 (Jun)
  measurement of, 128 (Feb)
  prediction of, 114 (Feb)
  quality of life assessment as a measurement of, 486 (May)
pediatric labeling, ASHP supports FDA's proposal for, 326 (Apr)
penicillin, pregnancy, adjustment of dosages in (abstr), 797 (Sept)
pentamidine, aerosolized, dapsone-pyrimethamine, vs, for prevention of PCP and toxoplasmosis (abstr), 792 (Sept)
percutaneous transluminal coronary angioplasty
  ciprostene therapy following, 441 (May)
  7E3 may prevent complications of, 452 (May)
  superior to drug therapy alone in improving physical activity, 437 (May)
perflubron, Imagent GI, update on, 880 (Nov)
pharmaceutical care, shifting emphasis on, 967 (Dec)
pharmaceutical industry
  economic analysis of, 132 (Feb)
  tax reforms and the, 328 (Apr)
pharmaceutical outcomes
  analysis of, 434 (May)
  research needed for, due to accelerated drug approvals, 128 (Feb)
pharmaceutical sales, long-term care market shows fastest growth in, 888 (Nov)
pharmacists
  managed-care, endorse universal access to health care, 543 (Jun)
  role of, 135 (Feb); 886 (Nov)
  role of, in managed care setting, 537 (Jun); 967 (Dec)
pharmacoeconomics
  drugs and services, and evaluation of, 365 (Apr)
  formulary decision making, influence on, 577 (Jun)
pharmacokinetic dosing service, automatic pharmacist-initiated, 589 (Jun)
pharmacy associations, coalitions of, present health care reform concerns, 608 (Jul)
pharmacy services, expansion of reported, 220 (Mar)
pirbuterol acetate, breath-activated inhaler for, Maxair Autohaler, update on, 815 (Oct)
Pneumocystis carinii pneumonia
  atovaquone as alternative Tx for, 341 (Apr)
  trimethoprim-sulfamethoxazole for prophylaxis against (abstr), 399 (Apr)
potassium citrate, Urocit-K, update on, 13 (Jan)
practice guidelines, use of, on the rise, 533 (Jun)
propofol
  Diprivan Injection, update on, 410 (May)
  midazolam, vs, in ICU sedation, 418 (May)
  recovery after anesthesia with, 114 (Feb)
pulmonary embolism
  anticoagulant therapy, duration of, in (abstr), 96 (Jan)
  thrombolysis plus heparin vs heparin alone for Tx of, 418 (May)

Q

quality of life
  assessment of, as patient outcome measurement, 486 (May)
  measures, importance of, in formulary decision making, 577 (Jun)

R

ramipril, myocardial infarction, for Tx of patients after, 889 (Nov)
ranitidine
  Medi-Cal removes from state formulary, 325 (Apr)
  omeprazole, vs, for Tx of ulcers (abstr), 654 (Jul)
  oral vs IV, 397 (Apr)
rationing, health care services, of, 233 (Mar)
respiratory distress syndrome, surfactant replacement therapy for Tx of, 49 (Jan)
rhinitis, allergic, loratadine for Tx of, 137 (Feb)
ribavirin for inhalation solution, Virazole, update on, 528 (Jun)
rifabutin
  fluconazole, and, in AIDS patients, 617 (Jul)
  Mycobacterium avium complex, for the Tx of, 827 (Oct); 975 (Dec)
  Mycobutin, update on, 210 (Mar); 815 (Oct)
rimantadine HCl, Flumadine, update on, 959 (Dec)
RU-486: See mifepristone

S

salmeterol
  asthma, for Tx of (abstr), 296 (Mar)
  focus on, 741 (Sept)
satumomab pendetide/indium-111-chloride imaging system, OncoScint CR/OV, update on, 307 (Apr)
seizure disorders, antiepileptic drugs, use of, in the management of, 154 (Feb)
sepsis
  interleukin-1 receptor antagonist (IL-1ra) increases survival rate in, 241 (Mar)
  murine monoclonal antibody E5 for Tx of, 312 (Apr)
serotonin receptor antagonists, use of, as antiemetic agents, 988 (Dec)
7E3, PTCA complications, may prevent, 452 (May)
simvastatin
  colestipol, or, vs combination of both for hypercholesterolemia, 21 (Jan)
  primary hypercholesterolemia, for Tx of (abstr), 296 (Mar)
sodium hyaluronate viscoelastic solution, AMO Vitrax, update on, 600 (Jul)
sotalol HCl, Betapace, update on, 7 (Jan)
streptokinase, routine administration of, not needed after PTCA for acute MI (abstr), 509 (May)
streptomycin, update on, 666 (Aug)
stroke, recurrent, ticlopidine for prevention of, 509 (May)
strontium-89 chloride injection, Metastron, update on, 722 (Sept)
structured-care plans, pharmacists' role in, 732 (Sept)
sumatriptan succinate
  focus on, 247 (Mar)
  Imitrex Injection, update on, 207 (Mar)
surfactant replacement therapy, respiratory distress syndrome, for Tx of, 49 (Jan)
systemic inflammatory response syndrome, severe, gram-negative infection may not be present in patients with (abstr), 512 (May)

T

tachycardia, ectopic atrial, adenosine for Tx of, 441 (May)
tacrine HCl
  Alzheimer's disease, nearing approval for Tx of, 544 (Jun)

SUBJECT INDEX TO VOLUME 28

Cognex, update on, 880 (Nov)
focus on, 679 (Aug)
tamoxifen citrate
breast cancer, for Tx of elderly patients with (abstr), 510 (May)
Nolvadex, update on, 606 (Jul)
teicoplanin, vancomycin, vs, for Tx of *C difficile*-associated diarrhea (abstr), 189 (Feb)
temazepam, Restoril, update on, 412 (May); 722 (Sept)
terazosin HCl, Hytrin, update on, 959 (Dec)
terbinafine HCl, Lamisil, update on, 411 (May)
terfenadine, macrolide antibiotics, and interactions with, 617 (Jul)
thalidomide, update on, 412 (May)
theophylline anhydrous, Theo-24, update on, 962 (Dec)
thrombolytic therapy
emergency room administration of (abstr), 189 (Feb)
findings regarding, in clinical trials, 558 (Jun)
hirudin as adjunct to, 451 (May)
IV, plus angioplasty vs angioplasty alone, 217 (Mar)
plus heparin vs heparin alone for Tx of pulmonary embolism, 418 (May)
prehospital administration of, 21 (Jan)
thyroid hormone therapy, parenteral, potential clinical applications for, 848 (Oct)
ticlopidine, aspirin, vs, for prevention of recurrent stroke (abstr), 509 (May)
tissue plasminogen activator (t-PA)
late administration of, reduces mortality, 15 (Jan)
new method of administering, 889 (Nov)
plus IV heparin, found to be optimal therapy in GUSTO trial, 543 (Jun)
trimethoprim/sulfamethoxazole
desensitization, in HIV-infected patients, 14 (Jan)
Pneumocystis carinii pneumonia, for prophylaxis against (abstr), 399 (Apr)
sensitivity to, less likely in patients severely ill with AIDS (abstr), 512 (May)
tuberculosis, drug-resistant, prevalence of, increasing (abstr), 798 (Sept)

U

ulcers
duodenal, combination therapy for Tx of recurrent, 321 (Apr)
gastroduodenal, diclofenac/misoprostol reduces, in osteoarthritic patients (abstr), 294 (Mar)
NSAID-induced, misoprostol as prophylaxis against (abstr), 708 (Aug)
user-fee program, FDA
effect of, on new drug approvals, 14 (Jan)
waiver criteria for, 887 (Nov)

V

vancomycin
teicoplanin, vs, for Tx of *C difficile*-associated diarrhea (abstr), 189 (Feb)
use of, increases in hematology/oncology patients (abstr), 653 (Jul)

W

warfarin, myocardial infarction, use of, after acute, 890 (Nov)
whey protein, hydrolyzed, for enteric feeding, Elementra, update on, 666 (Aug)

Z

zidovudine
early use of, in HIV+ patients, 828 (Oct)
HIV-exposed health care workers, use of, in, 708 (Aug)
zolpidem tartrate, Ambien, update on, 207 (Mar)

AUTHOR INDEX TO VOLUME 28

A

Abadi, Ashraf H.: See Steinwandt, Stephan M.
Akinwande, Kayode; Tse, C.S. Ted; Darab, M.; Madura, Albert; Cerceo R.; Al-Hani, A.: Strategic planning for the management of biotechnologic products: Development of a biotech committee, 773 (Sept)
Albertson, Timothy; Musallam, Nabil; Tharratt, R. Steven; Romac, Diane; Foulke, Garrett; Mowers, Robert; Panecek, Edward: Initiation of a clinical pharmacology consult service as a formulary management tool, 699 (Aug)
Al-Hani, A.: See Akinwande, Kayode
Ament, Paul W.; McGuire, Walter M.: Setting up automatic pharmacist-initiated pharmacokinetic dosing service, 589 (Jun)
Amidon, Thomas M.; Figueredo, Vincent; Wolfe, Christopher L.: Thrombolytics, adjuvant therapies in MI: What have we learned from the clinical trials?, 558 (Jun)
Ayres, Stephen M.: See Om, Anil

B

Baciewicz, Anne M.; Cowan, Ronald L.: Productivity and quality assessment associated with conversion from IV to oral ranitidine, 397 (Apr)
Bailey, Elaine M.; Sobel, Jack D.: Update on the prophylaxis, diagnosis, and treatment of candidal infections in hospitalized patients, 914 (Nov)
Barkin, Robert L.: See Stein, Z.L.G.
Bates, Phyllis: See Tse, C.S. Ted
Berman, Bernard A.: Asthma therapy in the '90s: A continuing controversy (letter), 395 (Apr)
Boivin, Paul: See Oh, William
Broisman, Larry: See Quercia, Robert A.
Brown, Douglas R: See Kitrenos, Jack G.

C

Calhoun, Jason: See Vibhagool, Asda
Cascino, Gregory D.: Antiepileptic drug management in patients with seizure disorders, 154 (Feb)
Cerceo, R: See Akinwande, Kayode
Chesnutt, Mark S.; Lazarus, Stephen C.: Asthma therapy in the '90s: A continuing controversy (letter reply), 395 (Apr)
Chow, Moses S.S.: See D'Angio, Richard
See Fankhauser, Martha P.
See Huwer, Margaret A.
See Kapusnik-Uner, Joan E.
See Kirtland, Heather
See Nicolau, David P.
See Owens, Norma J.
See Ponzillo, John J.
See Quercia, Robert A.
See Smith, Steven P.
See Steinwandt, Stephan M.
See Symonds, William T.
Clinton, J. Jarrett (interview with): Agency for Health Care Policy and Research: Improving health care through guidelines and outcomes research, 933 (Nov)
Coons, Stephen Joel; Kaplan, Robert M.: Quality of life assessment: Understanding its use as an outcome measure, 486 (May)
Cowan, Ronald L.: See Baciewicz, Anne M.
Crane, Vicki S.: How to use structured decision making in developing therapeutic, cost-effective formulary systems, 859 (Oct)

D

Dainer, Paul M.; DiPiro, Cecily R; Richards, Calita S.: Colorectal cancer: New pharmacologic strategies for prevention and treatment , 354 (Apr)
D'Angio, Richard; edited by Chow, Moses S.S.: Focus on salmeterol: A long-acting inhaled beta$_2$-adrenergic agonist for the treatment of asthma, 741 (Sept)
Darab, M.: See Akinwande, Kayode
Davidson, Michael H.; Rosenson, Robert S.; Mazzone, Theodore: From diagnosis to treatment: Focus on costs, safety, and efficacy of antihyperlipidemic agents, 262 (Mar)
Dempsey, Cindy L.; Kaley, Thomas C.; Zenkel, Jeffrey: Drug usage evaluation: Clarithromycin as sequential therapy, 999 (Dec)
DiPiro, Cecily R.: See Dainer, Paul M.

F

Fankhauser, Martha P.; Wendt, Jeanette K.; edited by Chow, Moses S.S.: Focus on sumatriptan: A selective serotonin-1D receptor agonist for the acute treatment of migraine, 247 (Mar)
Fedotin, Michael S.: *Helicobacter pylori*-associated ulcer disease: Current treatment options, 632 (Jul)
"No acid, no ulcer": Clarifying the maxim (letter reply), 780 (Sept)
Figueredo, Vincent: See Amidon, Thomas M.
Foulke, Garrett: See Albertson, Timothy

G

Gannon, Patrick: See Sesin, G. Paul
Gatty, Bob: Clinton's breakthrough drug committee: Will it stifle new drug development? 946 (Nov)
Formularies, rebates will lead drug cost containment efforts under health care reform, 1014 (Dec)
Health care reform: Pharmaceutical industry sees itself as 'whipping boy,' 872 (Oct)

Pharmaceutical industry loses fight on state Medicaid formularies in budget package, 800 (Sept)
PMA finances grassroots coalition to fight changes in Medicaid formularies, 714 (Aug)
Whatever happened to user fees and the FDA's promise to expedite new drug approvals? 656 (Jul)
Gollub, Steven B.: Combination medical therapy in the treatment of angina pectoris, 34 (Jan)
Gong, Sherman D.: Include biologics in year-end review of FDA approvals (letter), 507 (May)

H

Hess, Michael L.: See Om, Anil
Huwer, Margaret A; Pickworth, Kerry K.; edited by Chow, Moses S.S.: Focus on milrinone: Defining its role as an IV positive inotropic agent for congestive heart failure, 896 (Nov)

J

Julius, Hearee C.: Cost-effective management of DUE policy through a pharmacy clerkship, 789 (Sept)

K

Kaley, Thomas C.: See Dempsey, Cindy L.
Kaplan, Robert M.: See Coons, Stephen Joel
Kapusnik-Uner, Joan E.; Petersen, Carolyn; edited by Chow, Moses S.S.: Focus on rifabutin: Defining its role in the prevention and treatment of disseminated MAC infection, 975 (Dec)
Keefe, Carla C.: See Thompson, Dennis F.
Kirtland, Heather; Schutzer, Steven F.; Chow, Moses S.S.; edited by Chow, Moses S.S.: Focus on enoxaparin: An alternative for deep vein thrombosis prophylaxis offering the advantage of ease of use, 545 (Jun)
Kitrenos, Jack G.; Brown, Douglas R; Letting, Dorcas J.; Rotella, Denise L.: Clinical appropriateness, therapeutic equivalence, and cost of conversion to H_2 antagonist therapy, 86 (Jan)
Klein, Irwin; Ojamaa, Kaie; Powell, Saul: Potential clinical applications for parenteral thyroid hormone therapy, 848 (Oct)
Kovac, Anthony L.: Use of serotonin receptor antagonists in the prevention and treatment of nausea and vomiting, 988 (Dec)

L

Lazarus, Stephen C.: See Chesnutt, Mark S.
Letting, Dorcas J.: See Kitrenos, Jack G.
Loomis, John H.: See Passmore, John

M

Mader, Joan P.: See Vibhagool, Asda
Mader, Jon T.: See Vibhagool, Asda
Madura, Albert J.: See Tse, C.S. Ted
See Akinwande, Kayode
Mazzone, Theodore: See Davidson, Michael H.
McCall, Charles Y.; Wade, William E.: Results of a drug use evaluation of colloid for volume expansion, 503 (May)
McGhan, William F.: Pharmacoeconomics and the evaluation of drugs and services, 365 (Apr)
McGuire, Walter M.: See Ament, Paul W.
Moody, Steven B.; Sveska, Kim J.: Fluconazole dosing in renal impairment: A drug usage evaluation, 499 (May)
Mowers, Robert: See Albertson, Timothy
Musallam, Nabil: See Albertson, Timothy

N

Nicolau, David P.; Ross, Jack W.; Nightingale, Charles H; Quintiliani, Richard; edited by Chow, Moses S.S.: Focus on atovaquone: An alternative treatment for *Pneumocystis carinii* pneumonia, 341 (Apr)
Nightingale, Charles H.: See Nicolau, David P.
Nix, David E.: See Symonds, William T.
Norman, Dean C.: See Yoshikawa, Thomas T.

O

O'Connor, Gail: See Symonds, William T.
Oh, William; Boivin, Paul; Puleo, Frank; Thaute, Leslie A.: Surfactant replacement therapy for the treatment of respiratory distress syndrome, 49 (Jan)
Ojamaa, Kaie: See Klein, Irwin
Om, Anil; Ayres, Stephen M.; Hess, Michael L.: Managing low cardiac output states with inotropic medications, 388 (Apr)
Owens, Norma J.; edited by Chow, Moses S.S.: Focus on tacrine HCl: A cholinergic enhancer to treat Alzheimer's disease, 679 (Aug)

P

Panecek, Edward: See Albertson, Timothy
Passmore, John; Loomis, John H.: The role of IV enalaprilat in lowering blood pressure, 173 (Feb)
Petersen, Carolyn: See Kapusnik-Uner, Joan E.
Pickworth, Kerry K.: See Huwer, Margaret A.
Ponzillo, John J.; edited by Chow, Moses S.S.: Focus on felbamate: Beginning a new generation of anticonvulsant agents for the treatment of epilepsy, 837 (Oct)
Powell, Saul: See Klein, Irwin
Puleo, Frank: See Oh, William

Q

Quercia, Robert A.; Broisman, Larry; edited by Chow, Moses S.S.: Focus on loratadine: A new second-generation nonsedating H_1-receptor antagonist, 137 (Feb)
Quintiliani, Richard: See Nicolau, David P.

R

Richards, Calita S.: See Dainer, Paul M.
Romac, Diane: See Albertson, Timothy
Rosenson, Robert S.: See Davidson, Michael H.
Ross, Jack W.: See Nicolau, David P.
Rossiter, Alicia; Souney, Paul F.: Interaction between MAOIs and opioids: Pharmacologic and clinical considerations, 692 (Aug)
Rotella, Denise L.: See Kitrenos, Jack G.
Rutledge, David R.: See Steinwandt, Stephan M.

S

Schutzer, Steven F.: See Kirtland, Heather
Sedghi, Shahriar: See Zarling, Edwin J.
Sesin, G. Paul; Gannon, Patrick: Evaluation of IV ceftriaxone usage in a community-based hospital, 180 (Feb)
Skaer, Tracy L.: Applying pharmacoeconomic and quality-of-life measures to the formulary management process, 577 (Jun)
Smith Steven P.; edited by Chow, Moses S.S.: Focus on cladribine: A new agent for hairy cell leukemia with activity on resting and dividing lymphocytes, 621 (Jul)
Sobel, Jack D.: See Bailey, Elaine M.
Souney, Paul F.: See Rossiter, Alicia
Spenney, Jerry G.: "No acid, no ulcer": Clarifying the maxim (letter), 780 (Sept)
Stein, Z.L.G.; Barkin, Robert L.: On the safety of fluoroquinolones (letter), 291 (Mar)
Steinwandt, Stephan M.; Abadi, Ashraf H.; Rutledge, David R.; edited by Chow, Moses S.S.: Focus on bisoprolol: A once-daily beta blocker providing 24-hour blood pressure control with balanced renal and hepatic elimination, 453 (May)
Sveska, Kim J.: See Moody, Steven B.
Symonds, William T.; O'Connor, Gail; Nix, David E; edited by Chow, Moses S.S.: Focus on itraconazole: A broad-spectrum antifungal agent for the treatment of blastomycosis and histoplasmosis, 23 (Jan)

T

Tharratt, R. Steven: See Albertson, Timothy
Thaute, Leslie A.: See Oh, William
Thompson, Dennis F.; Keefe, Carla C.: Antineoplastic agents: Comparing off-label uses among authoritative drug compendia, 641 (Jul)
Tse, C.S. Ted; Madura, Albert J.: Can extended dosing intervals reduce drug costs while maintaining patient care? 648 (Jul)
Tse C.S. Ted; Madura, Albert J.; Bates, Phyllis: How effective are antibiotic streamlining programs in reducing length of hospital stay and cutting hospital costs? 868 (Oct)
Tse, C.S. Ted: See Akinwande, Kayode

V

Vibhagool, Asda; Calhoun, Jason; Mader, Joan P.; Mader, Jon T.: Therapy of bone and joint infections, 63 (Jan)

W

Wade, William E.: See McCall, Charles Y.
Weir, Brian: Antibiotic prophylaxis in cesarean section: Use of cost per case comparison to influence prescribing practices, 285 (Mar)
Wendt, Jeanette K.: See Fankhauser, Martha P.
Wolfe, Christopher L.: See Amidon, Thomas M.

Y

Yoshikawa, Thomas T.; Norman, Dean C.: Antibiotic therapy: What to consider when treating geriatric patients, 754 (Sept)

Z

Zarling, Edwin J.; Sedghi, Shahriar: Current and promising new therapies for inflammatory bowel disease, 466 (May)
Zenkel, Jeffrey: See Dempsey, Cindy L.